The - 173 G/C polymorphism of the promoter region macrophage migration inhibitory factor gene is not associated with incidence of pulmonary hamartoma

Polish Journal of Pathology

Volumn 58, Issue 3, 2007, Pages 189-192

  Kaznowska, Ewa ^a   Przybyłowska, Karolina ^b   Kulig, Andrzej ^c  

^a Tuberculosis and Pulmonary Diseases Specialistic Hospital   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

MACROPHAGE MIGRATION INHIBITION FACTOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HAMARTOMA; HUMAN; HUMAN TISSUE; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RISK ASSESSMENT;

ADULT; AGED; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAMARTOMA; HUMANS; INCIDENCE; LUNG DISEASES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROMOTER REGIONS (GENETICS);

EID: 36349019149     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Amoli MM, Donn RP, Thomson W, Hajeer AH, Garcia-Porrua C, Lueiro M, Ollier WE, Gonzalez-Gay MA: Macrophage migration inhibitory factor gene polymorphism is associated with sarcoidosis in biopsy proven erythema nodosum. J Rheumatol 2002, 29, 1671-1673.
2. Bacher M, Metz CN, Calandra T et al: An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci U S A 1996, 93, 7849-7854.
3. Bateson E: So-called hamartoma of the lung-a true neoplasm of fibrous connective tissue of the bronchi. Cancer 1973, 31, 1458-1467.
4. Baugh JA, Chitnis S, Donnelly SC, Monteiro J, Lin X, Plant BJ, Wolfe F, Gregersen PK, Bucala R: A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun 2002, 3, 170-176.
5. Bernhagen J, Calandra T, Mitchel RA et al: MIF is the pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 1993, 365, 756-759.
6. Bloom BR, Bennettm B: Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 1966, 153, 80-82.
7. Bucala R: MIF re-discovered: pituitary hormone and glucocorticoid-induced regulator of cytokine production. FASEB J 1996, 7, 19-24.
8. Calandra T, Bernhagen J, Mitchell RA, Mitchell J, Bucala R: The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 1994, 179, 1895-1902.
9. Dail D, Hammar S, Colby TV: Pulmonary pathology tumors. Springer. Heidelberg, New York 1994.
10. David JR: Delayed hypersensitivity in vitro: its mediation by cell free substances forms by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA 1966, 56, 72-77.
11. Donn R, Alourfi Z, De Benedetti F, Meazza C, Zeggini E, Lunt M, Stevens A, Shelley E, Lamb R, Ollier WE, Thomson W, Ray D: British Paediatric Rheumatology Study Group. Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheum 2002, 46, 2402-2409.
12. Donn RP, Plant D, Jury F, Richards HL, Worthington J, Ray DW, Griffiths CE: Macrophage migration inhibitory factor gene polymorphism is associated with psoriasis. J Invest Dermatol 2004, 123, 484-487.
13. Donn RP, Ray DW: Macrophage migration inhibitory factor: molecular, cellular and genetic aspects of a key neuroendocrine molecule. J Endocrinol 2004,182, 1-9.
14. Fudge T, Ochsner J, Mills N: Clinical spectrum of pulmonary hamartomas. Ann Thorac Surg 1980, 30, 36-39.
15. Hansen C, Holtveg H, Francis D, Rasch L, Bertelsen S: Pulmonary hamartoma. J Thorac Cardiovasc Surg 1992, 104, 674-678.
16. Kayser K: Analytical lung pathology. Springer. Heidelberg, Berlin, New York 1992.
17. Kayser K, Dunnwald D, Kazmierczak B, Bullerdiek J, Kaltner H, Zick Y, Andre S, Gabius H: Chromosomal aberrations, profiles of expression of growth-related markers including galectins and environmental hazards in relation to the incidence of chondroid pulmonary hamartomas. Pathol Res Pract, 2003, 199, 589-598.
18. Kaznowska E, Przybyłowska K, Kulig A: Promoter region-173 G/C polymorphism of macrophage migration inhibitory factor gene and pulmonary hamartoma. Valetudinaria Postȩpy Medycyny Klinicznej I Wojskowej 2005, 2, 107-109.
19. Lien YC, Hsu HS, Li WY, Wu YC, Hsu WH, Wang LS, Huang MH, Huang BS: Pulmonary hamartoma. J Chin Med Assoc 2004, 67, 21-26.
20. Miterski B, Drynda S, Boschow G, Klein W, Oppermann J, Kekow J, Epplen JT: Complex genetic predisposition in adult and juvenile rheumatoid arthritis. BMC Genet, 2004, 2-4.
21. Nishihira J: Macrophage migration inhibitory factor (MIF): Its essential role in the immune system and cell growth. J Interferon Cytokine Res 2000, 20, 751-762.
22. Shimizu T, Hizawa N, Honda A, Zhao Y, Abe R, Watanabe H, Nishihira J, Nishimura M, Shimizu H: Promoter region polymorphism of macrophage migration inhibitory factor is strong risk factor for young onset of extensive alopecia areata. Genes Immun 2005, 6, 285-289.
23. Van den Bosch J, Wagenaar S, Corrin B, Elbers J: Mesenchymoma of the lung (so-called hamartoma): a review of 154 parenchymal and endobronchial cases. Thorax 1987, 42, 790-793.